Patient demographics and disease characteristics at baseline
| Characteristic . | Previously untreated FL population (N = 40) . |
|---|---|
| Median age (range) at baseline, y | 56.5 (29-75) |
| Age category, n (%) | |
| ≥65 y | 6 (15.0) |
| <65 y | 34 (85.0) |
| Sex, n (%) | |
| Male | 20 (50.0) |
| Female | 20 (50.0) |
| FL grade at diagnosis, n (%) | |
| 1 | 10 (25.0) |
| 2 | 20 (50.0) |
| 3a | 9 (22.5) |
| Unclassified | 1 (2.5) |
| Ann Arbor stage at diagnosis, n (%) | |
| II | 3 (7.5) |
| III | 15 (37.5) |
| IV | 22 (55.0) |
| FLIPI risk group at diagnosis, n (%) | |
| Low (0-1) | 9 (22.5) |
| Intermediate (2) | 18 (45.0) |
| High (≥3) | 13 (32.5) |
| Eastern Cooperative Oncology Group performance status, n (%) | |
| 0 | 29 (72.5) |
| 1 | 11 (27.5) |
| Bone marrow involvement, n (%) | 20 (50.0) |
| LDH elevated, n (%) | 7 (17.5) |
| Bulky disease (≥7 cm), n (%) | 9 (22.5) |
| Median SPD (range) of indicator lesions, mm2 | 2821 (740-23 025) |
| Characteristic . | Previously untreated FL population (N = 40) . |
|---|---|
| Median age (range) at baseline, y | 56.5 (29-75) |
| Age category, n (%) | |
| ≥65 y | 6 (15.0) |
| <65 y | 34 (85.0) |
| Sex, n (%) | |
| Male | 20 (50.0) |
| Female | 20 (50.0) |
| FL grade at diagnosis, n (%) | |
| 1 | 10 (25.0) |
| 2 | 20 (50.0) |
| 3a | 9 (22.5) |
| Unclassified | 1 (2.5) |
| Ann Arbor stage at diagnosis, n (%) | |
| II | 3 (7.5) |
| III | 15 (37.5) |
| IV | 22 (55.0) |
| FLIPI risk group at diagnosis, n (%) | |
| Low (0-1) | 9 (22.5) |
| Intermediate (2) | 18 (45.0) |
| High (≥3) | 13 (32.5) |
| Eastern Cooperative Oncology Group performance status, n (%) | |
| 0 | 29 (72.5) |
| 1 | 11 (27.5) |
| Bone marrow involvement, n (%) | 20 (50.0) |
| LDH elevated, n (%) | 7 (17.5) |
| Bulky disease (≥7 cm), n (%) | 9 (22.5) |
| Median SPD (range) of indicator lesions, mm2 | 2821 (740-23 025) |
FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactate dehydrogenase; SPD, sum of the products of the diameters.